ISSUE 1463
| Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
The FDA has approved tavaborole 5% solution (Kerydin – Anacor Pharmaceuticals) for topical treatment of toenail onychomycosis due to Trichophyton rubrum or Trichophyton mentagrophytes. It is the first oxaborole antifungal drug to be approved for this indication.
STANDARD TREATMENT — Toenail onychomycosis is most often caused by the dermatophytes T. rubrum and T. mentagrophytes, and rarely by nondermatophyte molds and yeasts. Oral terbinafine and oral itraconazole are the drugs of choice for treatment of dermatophyte toenail onychomycosis, but even with prolonged treatment (3 months), cure rates are low and relapse rates are high. Drug interactions and adverse effects, including gastrointestinal symptoms, serious skin reactions, and severe hepatic toxicity are common.1,2 Terbinafine is generally preferred over
... more- Antifungal drugs. Treat Guidel Med Lett 2012; 10:61.
- M Ameen et al. British Association of Dermatologists' guidelines for the management of onychomycosis 2014. Br J Dermatol 2014; 171:937.
- AK Gupta et al. Therapies for onychomycosis: a systematic review and network meta-analysis of mycological cure. J Am Podiatr Med Assoc 2014 July 17 (epub).
- Efinaconazole topical solution (Jublia) for onychomycosis. Med Lett Drugs Ther 2014; 56:88.
- AK Gupta et al. Topical therapy for toenail onychomycosis: an evidence-based review. Am J Clin Dermatol 2014; 15:489.
- Laser treatment of onychomycosis. Med Lett Drugs Ther 2013; 55:15.
- X Hui et al. In vitro penetration of a novel oxaborole antifungal (AN2690) into the human nail plate. J Pharm Sci 2007; 96:2622.
Would you like to read the rest of this article? Gain access below.
- Print version published and mailed biweekly (26 issues/year)
- Unlimited online access to current and past issues (1988 - present)
- Mobile App for iOS, Android, and Kindle Fire
- FREE online per issue CME/CE
Article code: 1463d
Electronic, downloadable article - $45
